Adjuvant immunotherapy with BCG in squamous cell bronchial carcinoma.

Jansen, Henk M.; The, T. H.; Orie, N. G. M.

doi:10.1136/thx.35.10.781

Cited by 23 publications

(5 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several other clinical trials are in progress, involving malignant melanoma, bronchus (Ludwig Lung Cancer Group, 1978) and gastric carcinoma (Dykes & Trejdosiewicz, 1978) but no information is yet available on subsequent follow-up. Combinations of surgery with immune stimulants other than CP, such as BCG (Bier et al, 1980;Jansen et al, 1980), poly A-poly U (Lacour et al, 1980) and interferon (Ikic et al, 1981a,b,c) have also given beneficial results.…”

Section: Discussionmentioning

confidence: 99%

Lower relapse rates after neighbourhood injection of Corynebacterium parvum in operable cervix carcinoma

Mignot¹,

Lens²,

Drexhage³

et al. 1981

Br J Cancer

View full text Add to dashboard Cite

Summary.-The effect of adjuvant immunotherapy with a single neighbourhood injection of 2 mg C. parvum (CP) was investigated in a randomized study involving 43 patients with carcinoma of the cervix uteri, all of whom were treated by radical surgery.. All patients had carcinoma confined to the cervix, the upper part of the vagina or the parametrial region. When the malignancy had spread to the parametrial region, additional postoperative radiotherapy was given. 22 patients received immunotherapy 10 days before surgery, whereas the remaining 21 control patients received no immune stimulation. Only minor side effects of CP were encountered.Follow-up shows a relapse rate of 5% in the CP treated group and of 29% in the controls (P<0-05). A further 15 patients with more advanced malignancies were added to our studies. In these, CP stimulation had no effect on relapse rates, but the relapse-free intervals were longer after immune stimulation: control 3-5 months (mean) ± 1-5 (s.d.), CP 13-0 months +7-0 (P<0-05).The number of peripheral T cells and the ability to become sensitized to DNCB were increased after CP stimulation. A decrease was found in the number of blood monocytes and the number of monocytes capable of transforming into active macrophages, indicating a possible sequestration of these cells in the tissues.

show abstract

Section: Discussionmentioning

confidence: 99%

Lower relapse rates after neighbourhood injection of Corynebacterium parvum in operable cervix carcinoma

Mignot¹,

Lens²,

Drexhage³

et al. 1981

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…26 Jansen and associates studied the effects of BCG scarification and scarification plus intrapleural BCG and were unable to demonstrate any difference between systemic and combined systemic and intrapleural treatment. 63,64 In both groups who had squamous cell carcinoma treated with BCG, recurrence rates decreased significantly during follow-up. Favorable clinical outcome was accompanied by an increased cellular immune reactivity.…”

Section: Bcg Immunotherapy Of Lung Cancermentioning

confidence: 98%

“…The most widely investigated immunotherapeutic agents in lung cancer are BCG 49,53,54 and cell-wall fractions of BCG. 43,84,119 These agents have been given by aerosol, 24 intradermally, 1,26,27,38,40,60,63,64,83,102,104,108,115 intrapleurally, 64,74,75,[86][87][88][89]107,131 and intratumorally. 43,[56][57][58]82,91 AEROSOLIZED BCG.…”

Section: Bcg Immunotherapy Of Lung Cancermentioning

confidence: 99%

Immunotherapy of Lung Cancer

Matthay¹

1982

Semin Respir Crit Care Med

View full text Add to dashboard Cite

“…The role of immunotherapy using BCG in squamous carcinoma remains controversial (Jansen, The and Orie, 1980). As in earlier years, the message for lung cancer seems to be well summarized by the words King Edward VII used about tuberculosis-'if preventable, why not prevent?…”

Section: Treatmentmentioning

confidence: 99%

Recent advances in respiratory medicine

Flenley

1983

Postgraduate Medical Journal

View full text Add to dashboard Cite

In the past tuberculosis so dominated both public and professional views of respiratory medicine that it seemed obvious that the speciality must atrophy, at least in developed countries, when effective therapy for tuberculosis became available. The reality has been rather different. New discoveries in understanding of pathogenesis, in diagnostic methods, and above all in treatment, continue to keep respiratory medicine to the fore amongst the major sub-specialities of medicine, a position that the burden of such disease on society clearly merits. The topics chosen for this review are necessarilv personal, but aim to indicate some areas where these discoveries are being applied in clinical practice today.

show abstract

Adjuvant immunotherapy with BCG in squamous cell bronchial carcinoma.

Abstract: Fifty-four patients with evidence of locally advanced primary squamous cell bronchial carcinoma (SCC), and three patients with adenocarcinoma (AC) had

Cited by 23 publications

References 14 publications

Lower relapse rates after neighbourhood injection of Corynebacterium parvum in operable cervix carcinoma

Lower relapse rates after neighbourhood injection of Corynebacterium parvum in operable cervix carcinoma

Immunotherapy of Lung Cancer

Recent advances in respiratory medicine

Contact Info

Product

Resources

About